Allianz Asset Management
VIRX

Allianz Asset Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Allianz Asset Management’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-608
Closed -$911K – 2405
2014
Q3 		$911K Buy
+608
New +$880K ﹤0.01% 1689
2013
Q4 		– Sell
-766
Closed -$798K – 1916
2013
Q3 		$798K Buy
766
+218
+40% +$233K ﹤0.01% 1414
2013
Q2 		$597K Buy
+548
New +$611K ﹤0.01% 1453

Other funds holding VIRX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Allianz Asset Management's VIRX Position: Q4 2014 in Review

Allianz Asset Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2014, closing a stake of 608 shares — an estimated $911K sold.

Allianz Asset Management first reported a position in VIRX in Q2 2013 and held it in 3 quarters. The position peaked at $911K in Q3 2014. 78 funds tracked by Wall St. Rank hold VIRX as of Q4 2014.

  • Allianz Asset Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2014 after selling out during the quarter.
  • Allianz Asset Management sold 608 Viracta Therapeutics, Inc. Common Stock shares in Q4 2014, an estimated $911K.
  • Allianz Asset Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 3 quarters.
  • Allianz Asset Management's Viracta Therapeutics, Inc. Common Stock position peaked at $911K in Q3 2014.
  • 78 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2014.

Based on Allianz Asset Management's 13F filing for Q4 2014, filed 17 Feb 2015.